MedTrace Logo

Intratumoral DNX-2401 for High Grade Pediatric Brain Tumors

NCT07424092 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2026-05-15

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if intratumoral administration of DNX-2401 works to treat recurrent and refractory high grade brain tumors in children and young adults. It will also learn about the safety of DNX-2401.

The main questions it aims to answer are:

* Does a single intratumoral administration of DNX-2401 elicit tumor response and improve survival?
* Is a single intratumoral administration of DNX-2401 safe and well tolerated?

Participants will:

* Undergo surgery for tumor biopsy followed by a single intratumoral administration of DNX-2401
* Visit the clinic periodically for checkups and tests

Conditions

Interventions

BIOLOGICAL

DNX-2401

Single intratumoral infusion of 5 × 10\^10 viral particles of DNX-2401 after tumor biopsy.

Sponsors & Collaborators

  • Princess Maxima Center for Pediatric Oncology

    collaborator OTHER

  • Asociación Española contra el Cáncer

    collaborator OTHER

  • Clinica Universidad de Navarra, Universidad de Navarra

    lead OTHER

Principal Investigators

  • Jaime Gállego Pérez de Larraya, M.D., Ph.D. · Cancer Center Clínica Universidad de Navarra

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Max Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-12
Primary Completion
2029-05-31
Completion
2029-05-31
FDA Drug
Yes

Countries

  • Netherlands
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07424092 on ClinicalTrials.gov